In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime

Cefepime is frequently prescribed to treat infections caused by AmpC-producing Gram-negative bacteria. CMY-2 is the most common plasmid-mediated AmpC (pAmpC) β-lactamase. Unfortunately, CMY variants conferring enhanced cefepime resistance have been reported. Here, we describe the evolution of CMY-2...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrob Agents Chemother
Hauptverfasser: Pires, João, Taracila, Magdalena, Bethel, Christopher R., Doi, Yohei, Kasraian, Sara, Tinguely, Regula, Sendi, Parham, Bonomo, Robert A., Endimiani, Andrea
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2015
Schlagworte:
Mechanisms of Resistance
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4649241/
https://ncbi.nlm.nih.gov/pubmed/26392491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01804-15
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge